Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831155 · ClinicalTrials.gov registry record · Phase 1
Extinction Based Treatment for Nicotine Dependence
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 257
- Enrollment target
NCT00831155: Completed Phase 1 study, sponsored by Duke University.
NCT00831155 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 257 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (328% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00831155, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 257 participants
- Enrollment target
Study Summary
The purpose of this study is to test two quit smoking therapies and to study brain function while each therapy is being used. You will be randomly assigned (like flipping a coin) to one of the two groups. The first therapy is Extinction-Based therapy (EBT). If you are in this group, you will switch to smoking denicotinized cigarettes while wearing a 21 mg/d nicotine patch for one month prior to your quit date. The second therapy is a standard Nicotine Replacement therapy (NRT). If you are in this group, you will smoke your usual brand of cigarettes up to the quit date. Following the quit date, both groups will undergo standard nicotine replacement therapy (21 mg/d for 6 weeks; 14 mg/d for 2 weeks, 7 mg/d for 2 weeks). In addition to the above, we will recruit a sample of former smokers who are now regular users of e-cigarettes. This group \[ECIG\] will undergo the same screening and baseline assessments as the EBT and NRT groups up to the completion of fMRI1.
Interventions
- DRUG Nicotine Patches, Denicotinized Cigarettes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
What the finished NCT00831155 record still lists
NCT00831155 is an interventional study that assigns participants to a tested intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (328% higher).
The record links to 0 conditions, and to 1 intervention - of which Nicotine Patches, Denicotinized Cigarettes is the first listed.
NCT00831155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00831155 about?
NCT00831155 is a clinical study titled "Extinction Based Treatment for Nicotine Dependence". The purpose of this study is to test two quit smoking therapies and to study brain function while each therapy is being used. You will be randomly assigned (like flipping a coin) to one of the two groups. The first therapy is Extinction-Based therapy (EBT). If you are in this group, you will switch ...
What is the current status of trial NCT00831155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 257 participants. The study started on 2009-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00831155?
The interventions under investigation include: Nicotine Patches, Denicotinized Cigarettes (DRUG).
Who is sponsoring clinical trial NCT00831155?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00831155's enrollment target sits among peer trials
257 168th of 2000 higher than 1,833 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia